title: Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program.
abstract: BACKGROUND
  The Glivec International Patient Assistance Program (GIPAP) is designed to provide access to the cancer therapy Imatinib (Glivec⊠), which is indicated for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
  
  
  OBJECTIVE
  To identify factors those influence the quality of care and structural improvements. Design . Physicians (n=50), hospital administrators (n=10) and Ministry of Health officials (n=7) in 39 developing countries participated in qualitative interviews. The interviews focused on the impact of GIPAP on service delivery, patient tracking systems and cancer registries, health financing, and workforce.
  
  
  RESULTS
  Service delivery, patient management, access to care, diagnostic capacity, and health workers' skills improved at participants' institutions following implementation of GIPAP.
  
  
  CONCLUSIONS
  Positive institutional changes that improve care of CML/GIST patients arose from GIPAP. Some of these changes may strengthen institutions' capacity to treat other diseases as well. The GIPAP model could be deployed to improve access to care for patients with other chronic diseases.
authors.forename: Joël
authors.initials: J
authors.lastname: Ladner
authors.forename: Ebru
authors.initials: E
authors.lastname: Tekinturhan
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Tavolacci
authors.forename: Etienne
authors.initials: E
authors.lastname: Audureau
authors.forename: Joseph
authors.initials: J
authors.lastname: Saba
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000600:supply & distribution* / Q000627:therapeutic use; D001549:Benzamides / Q000191:economics / Q000600:supply & distribution* / Q000627:therapeutic use; D003906:Developing Countries; D006297:Health Services Accessibility; D006801:Humans; D000068877:Imatinib Mesylate; D007391:International Cooperation; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology; D010879:Piperazines / Q000191:economics / Q000600:supply & distribution* / Q000627:therapeutic use; D015397:Program Evaluation; D011743:Pyrimidines / Q000191:economics / Q000600:supply & distribution* / Q000627:therapeutic use; D058996:Quality Improvement; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate